Anna Rita Franco Migliaccio

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3666708/anna-rita-franco-migliaccio-publications-by-year.pdf
Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

170 papers	8,477 citations	33 h-index	91 g-index
182 ext. papers	9,590 ext. citations	4.6 avg, IF	5 L-index

#	Paper	IF	Citations
170	Resident Self-Tissue of Proinflammatory Cytokines Rather Than Their Systemic Levels Correlates with Development of Myelofibrosis in Mice.. *Biomolecules*, **2022**, 12,	5.9	1
169	The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in the Mice.. *Frontiers in Oncology*, **2022**, 12, 853484	5.3	0
168	The Glucocorticoid Receptor-Dependent Stress Response in Human Erythropoiesis Is BCL11A-Dependent. *Blood*, **2021**, 138, 939-939	2.2	
167	The CXCL1 Inhibitor Reparixin Rescues Myelofibrosis in the Gata1low Model of the Disease. *Blood*, **2021**, 138, 3579-3579	2.2	
166	Treatment of Myelofibrosis Patients with the TGF-β1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production. *Blood*, **2021**, 138, 142-142	2.2	5
165	Under the Control of a Promoter Rescues the Erythroid but Not the Megakaryocytic Phenotype Induced by the Mutation in Mice. *Frontiers in Genetics*, **2021**, 12, 720552	4.5	
164	The Glucocorticoid Receptor Polymorphism Landscape in Patients With Diamond Blackfan Anemia Reveals an Association Between Two Clinically Relevant Single Nucleotide Polymorphisms and Time to Diagnosis. *Frontiers in Physiology*, **2021**, 12, 745032	4.6	1
163	An Outline of the Outset of Thrombopoiesis in Human Embryos At Last. *Cell Stem Cell*, **2021**, 28, 363-365	18	2
162	The Role of Megakaryocytes in Myelofibrosis. *Hematology/Oncology Clinics of North America*, **2021**, 35, 191-203	3.1	3
161	Evolution and new frontiers of histology in bio-medical research. *Microscopy Research and Technique*, **2021**, 84, 217-237	2.8	3
160	TGF-β protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis. *JCI Insight*, **2021**, 6,	9.9	5
159	Role of β1 integrin in thrombocytopoiesis. *Faculty Reviews*, **2021**, 10, 68	1.2	0
158	Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis. *Frontiers in Oncology*, **2020**, 10, 584541	5.3	3
157	Inhibition of P-Selectin Rescues the Phenotype of a Novel Genetic Animal Model for Idiopathic Pulmonary Fibrosis. *Blood*, **2020**, 136, 29-29	2.2	
156	Preclinical Rationale for the Use of Crizanlizumab (SEG101) in Myelofibrosis. *Blood*, **2020**, 136, 26-27	2.2	2
155	Rationale for and Results of a Phase I Study of the TGF-β1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial. *Blood*, **2020**, 136, 6-8	2.2	6
154	Novel targets to cure primary myelofibrosis from studies on Gata1 mice. *IUBMB Life*, **2020**, 72, 131-141	4.7	4

153	Genetic disarray follows mutant KLF1-E325K expression in a congenital dyserythropoietic anemia patient. *Haematologica*, **2019**, 104, 2372-2380	6.6	10
152	Dexamethasone Predisposes Human Erythroblasts Toward Impaired Lipid Metabolism and Renders Their Expansion Highly Dependent on Plasma Lipoproteins. *Frontiers in Physiology*, **2019**, 10, 281	4.6	7
151	Shared and Tissue-Specific Expression Signatures between Bone Marrow from Primary Myelofibrosis and Essential Thrombocythemia. *Experimental Hematology*, **2019**, 79, 16-25.e3	3.1	4
150	Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology. *F1000Research*, **2019**, 8,	3.6	12
149	Altered Megakaryocytes Are Associated with Development of Pulmonary Fibrosis in Mice Carrying the Hypomorphic Gata1low Mutation. *Blood*, **2019**, 134, 2336-2336	2.2	
148	Phosphoproteomic Landscaping Identifies Non-canonical cKIT Signaling in Polycythemia Vera Erythroid Progenitors. *Frontiers in Oncology*, **2019**, 9, 1245	5.3	4
147	GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy. *Expert Review of Hematology*, **2018**, 11, 169-184	2.8	17
146	Dissecting physical structure of calreticulin, an intrinsically disordered Ca-buffering chaperone from endoplasmic reticulum. *Journal of Biomolecular Structure and Dynamics*, **2018**, 36, 1617-1636	3.6	8
145	Biology of Erythropoiesis, Erythroid Differentiation, and Maturation **2018**, 297-320.e14		1
144	Whirling Platelets Away for Transfusion. *Cell*, **2018**, 174, 503-504	56.2	3
143	Remembering Ihor Lemischka—The scientist's scientist. *Experimental Hematology*, **2018**, 58, 1-4	3.1	
142	AVID200, a Potent Trap for TGF-β Ligands Inhibits TGF-β Signaling in Human Myelofibrosis. *Blood*, **2018**, 132, 1791-1791	2.2	15
141	The Hypomorphic Gata1low Mutation Induces Fibrosis in Multiple Organs. *Blood*, **2018**, 132, 3059-3059	2.2	
140	Human GATA1 Driven By the Human Retro LCR/εGlobin Promoter Rescues the Erythroid but Not the Megakaryocytic Phenotype Induced in Mice By the Gata1low Mutation. *Blood*, **2018**, 132, 1042-1042	2.2	
139	A vicious interplay between genetic and environmental insults in the etiology of blood cancers. *Experimental Hematology*, **2018**, 59, 9-13	3.1	3
138	Concise Review: Advanced Cell Culture Models for Diamond Blackfan Anemia and Other Erythroid Disorders. *Stem Cells*, **2018**, 36, 172-179	5.8	5
137	Megakaryocyte Contribution to Bone Marrow Fibrosis: many Arrows in the Quiver. *Mediterranean Journal of Hematology and Infectious Diseases*, **2018**, 10, e2018068	3.2	23
136	The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera. *Experimental Hematology*, **2017**, 50, 53-76	3.1	9

135	The thrombopoietin/MPL axis is activated in the Gata1 mouse model of myelofibrosis and is associated with a defective RPS14 signature. *Blood Cancer Journal*, **2017**, 7, e572	7	19
134	Miss Piggy on the catwalk again. *Blood*, **2017**, 130, 2153-2154	2.2	
133	Calreticulin: Challenges Posed by the Intrinsically Disordered Nature of Calreticulin to the Study of Its Function. *Frontiers in Cell and Developmental Biology*, **2017**, 5, 96	5.7	11
132	Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. *Journal of Clinical Investigation*, **2017**, 127, 1316-1320	15.9	47
131	Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis. *Experimental Hematology*, **2016**, 44, 1138-1155.e4	3.1	30
130	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
129	Phosphoproteomic Landscaping Unveils Constitutive cKIT Activation in Human Erythroblasts from Polycythemia Vera (PV) Patients. *Blood*, **2016**, 128, 399-399	2.2	
128	The Carboxy-Terminal Domain of Calreticulin (CALR) Exports the Glucocorticoid Receptor (GR) from the Nucleus to the Cytoplasm of Human Erythroid Cells Resetting Their Stress Response. *Blood*, **2016**, 128, 545-545	2.2	
127	To condition or not to condition-That is the question: The evolution of nonmyeloablative conditions for transplantation. *Experimental Hematology*, **2016**, 44, 706-12	3.1	3
126	P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1 low Model of Myelofibrosis. *Stem Cells*, **2016**, 34, 67-82	5.8	26
125	2p15-p16.1 microdeletions encompassing and proximal to BCL11A are associated with elevated HbF in addition to neurologic impairment. *Blood*, **2015**, 126, 89-93	2.2	55
124	CD14+ cells from peripheral blood positively regulate hematopoietic stem and progenitor cell survival resulting in increased erythroid yield. *Haematologica*, **2015**, 100, 1396-406	6.6	39
123	Tribute to Donald Metcalf. *Stem Cells*, **2015**, 33, 3397-421	5.8	
122	Dexamethasone targeted directly to macrophages induces macrophage niches that promote erythroid expansion. *Haematologica*, **2015**, 100, 178-87	6.6	38
121	Activation of non-canonical TGF-β signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis. *Blood Cells, Molecules, and Diseases*, **2015**, 54, 234-41	2.1	24
120	Cord Blood Hematopoiesis **2015**, 27-37		0
119	A novel interaction between megakaryocytes and activated fibrocytes increases TGF-β bioavailability in the Gata1(low) mouse model of myelofibrosis. *American Journal of Blood Research*, **2015**, 5, 34-61	1.6	14
118	Glucocorticoid Regulation of Erythropoiesis in Humans: A Study of Patients with Cushing's Disease. *Blood*, **2015**, 126, 2135-2135	2.2	

117	An Inhibitor of TGF-β Promotes Proliferation of Normal but Not MPN Hematopoietic Cells and Is a Candidate Therapeutic Agent for the Treatment of MPN Patients Carrying JAK2 V617F or Calr pQ365fs Mutations. *Blood*, **2015**, 126, 4089-4089	2.2	
116	The JAK2 V617F Mutation Disrupts the Regulatory Activity Exerted By Calreticulin on the Glucocorticoid Receptor in Erythroid Cells. *Blood*, **2015**, 126, 5216-5216	2.2	
115	Abnormal P-selectin localization during megakaryocyte development determines thrombosis in the gata1low model of myelofibrosis. *Platelets*, **2014**, 25, 539-47	3.6	12
114	Mononuclear cells from a rare blood donor, after freezing under good manufacturing practice conditions, generate red blood cells that recapitulate the rare blood phenotype. *Transfusion*, **2014**, 54, 1059-70	2.9	9
113	Identification of NuRSERY, a new functional HDAC complex composed by HDAC5, GATA1, EKLF and pERK present in human erythroid cells. *International Journal of Biochemistry and Cell Biology*, **2014**, 50, 112-22	5.6	19
112	The Lombardy Rare Donor Programme. *Blood Transfusion*, **2014**, 12 Suppl 1, s249-55	3.6	4
111	Transfusion-independent (β0)-thalassemia after bone marrow transplantation failure: proposed involvement of high parental HbF and an epigenetic mechanism. *American Journal of Blood Research*, **2014**, 4, 27-32	1.6	6
110	The role of glucocorticoid receptor (GR) polymorphisms in human erythropoiesis. *American Journal of Blood Research*, **2014**, 4, 53-72	1.6	8
109	Stem cell-derived erythrocytes as upcoming players in blood transfusion. *ISBT Science Series*, **2013**, 8, 165-171	1.1	2
108	Transcriptomic and phospho-proteomic analyzes of erythroblasts expanded in vitro from normal donors and from patients with polycythemia vera. *American Journal of Hematology*, **2013**, 88, 723-9	7.1	15
107	Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis. *Blood*, **2013**, 121, 3345-63	2.2	63
106	The Making Of Erythroid Islands In HEMA Culture. *Blood*, **2013**, 122, 939-939	2.2	
105	The expression of the glucocorticoid receptor in human erythroblasts is uniquely regulated by KIT ligand: implications for stress erythropoiesis. *Stem Cells and Development*, **2012**, 21, 2852-65	4.4	20
104	The potential of stem cells as an in vitro source of red blood cells for transfusion. *Cell Stem Cell*, **2012**, 10, 115-9	18	61
103	Ex-vivo expansion of red blood cells: how real for transfusion in humans?. *Blood Reviews*, **2012**, 26, 81-95	11.1	36
102	A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation. *Blood*, **2012**, 120, 3112-7	2.2	29
101	Concise review: stem cell-derived erythrocytes as upcoming players in blood transfusion. *Stem Cells* , **2012**, 30, 1587-96	5.8	44
100	Ex vivo generated red cells as transfusion products. *Stem Cells International*, **2012**, 2012, 615412	5	2

99	Blood in a dish: In vitro synthesis of red blood cells. *Drug Discovery Today Disease Mechanisms*, **2011**, 8, e3-e8		8
98	Under HEMA conditions, self-replication of human erythroblasts is limited by autophagic death. *Blood Cells, Molecules, and Diseases*, **2011**, 47, 182-97	2.1	19
97	Recovery and Biodistribution of Ex Vivo Expanded Human Erythroblasts Injected into NOD/SCID/IL2R□mice. *Stem Cells International*, **2011**, 2011, 673752	5	11
96	Phenotypic definition of the progenitor cells with erythroid differentiation potential present in human adult blood. *Stem Cells International*, **2011**, 2011, 602483	5	12
95	The dominant negative □soform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients. *Blood*, **2011**, 118, 425-36	2.2	33
94	Increased frequency of the glucocorticoid receptor A3669G (rs6198) polymorphism in patients with Diamond-Blackfan anemia. *Blood*, **2011**, 118, 473-4	2.2	13
93	GATA2 finds its macrophage niche. *Blood*, **2011**, 118, 2647-9	2.2	5
92	Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidase. *Journal of Biological Chemistry*, **2011**, 286, 27630-8	5.4	66
91	Compensated variability in the expression of globin-related genes in erythroblasts generated ex vivo from different donors. *Transfusion*, **2010**, 50, 672-84	2.9	9
90	Humanized culture medium for clinical expansion of human erythroblasts. *Cell Transplantation*, **2010**, 19, 453-69	4	57
89	Getting personal with B19 parvovirus. *Blood*, **2010**, 115, 922-3	2.2	3
88	Dynamic regulation of Gata1 expression during the maturation of conventional dendritic cells. *Experimental Hematology*, **2010**, 38, 489-503.e1	3.1	10
87	Evidence for organ-specific stem cell microenvironments. *Journal of Cellular Physiology*, **2010**, 223, 460-70	7	5
86	CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin. *Journal of Cellular Physiology*, **2010**, 225, 490-9	7	16
85	EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors. *PLoS ONE*, **2010**, 5, e12015	3.7	18
84	Increased differentiation of dermal mast cells in mice lacking the Mpl gene. *Stem Cells and Development*, **2009**, 18, 1081-92	4.4	3
83	Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells. *Experimental Hematology*, **2009**, 37, 559-72	3.1	25
82	NF-E2 overexpression delays erythroid maturation and increases erythrocyte production. *British Journal of Haematology*, **2009**, 146, 203-17	4.5	21

81	Removal of the spleen in mice alters the cytokine expression profile of the marrow micro-environment and increases bone formation. *Annals of the New York Academy of Sciences*, **2009**, 1176, 77-86	6.5	7
80	Long-term storage does not alter functionality of in vitro generated human erythroblasts: implications for ex vivo generated erythroid transfusion products. *Transfusion*, **2009**, 49, 2668-79	2.9	5
79	Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis. *Expert Review of Hematology*, **2009**, 2, 315-334	2.8	24
78	Erythroid cells in vitro: from developmental biology to blood transfusion products. *Current Opinion in Hematology*, **2009**, 16, 259-68	3.3	52
77	Gata1 expression driven by the alternative HS2 enhancer in the spleen rescues the hematopoietic failure induced by the hypomorphic Gata1low mutation. *Blood*, **2009**, 114, 2107-20	2.2	25
76	The Marine Tunicate-Derived Cyclic Depsipeptide Aplidin Restores Functional Hematopoiesis in the Marrow of the Gata1low Mouse Model of Myelofibrosis.. *Blood*, **2009**, 114, 3914-3914	2.2	1
75	the □soform of the Glucocorticoid Receptor Is Ontogenetically Activated and Predicts Poor Ex-Vivo Expansion of Erythroid Cells From Adult Blood.. *Blood*, **2009**, 114, 642-642	2.2	
74	The Final Cellular Output in Human Erythroid Massive Amplification Culture (HEMA) Is Determined by Dynamic Interactions Between Immature and Mature Cell Populations.. *Blood*, **2009**, 114, 3156-3156	2.2	1
73	Ontogenic-Specific Increasesin HDAC1 Activity and Transcription Factor Association During the Maturation of Human Adult Erythroblasts in Vitro.. *Blood*, **2009**, 114, 1978-1978	2.2	
72	Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease. *Experimental Hematology*, **2008**, 36, 158-71	3.1	45
71	Animal Models of Myelofibrosis **2008**, 713-723		1
70	Histone deacetylase inhibitors and hemoglobin F induction in beta-thalassemia. *International Journal of Biochemistry and Cell Biology*, **2008**, 40, 2341-7	5.6	12
69	Thrombopoietin inhibits murine mast cell differentiation. *Stem Cells*, **2008**, 26, 912-9	5.8	16
68	Human Erythroblasts Generated in Vitro Remain Functional with a Normal Karyotype 8 Years after Cryopreservation: Implications for Ex Vivo Generated Erythroid Transfusion Products.. *Blood*, **2008**, 112, 2303-2303	2.2	1
67	Dynamic Pattern of Adhesion Receptor Expression during the Maturation of Ex-Vivo Generated Human Adult and Neonatal Erythroid Cells.. *Blood*, **2008**, 112, 997-997	2.2	1
66	Aplidin Improves Megakaryocytopoiesis and Halts Neo-Angiogenesis in the Gata1low Murine Model of Myelofibrosis. *Blood*, **2008**, 112, 2787-2787	2.2	
65	Protein kinase Calpha is differentially activated during neonatal and adult erythropoiesis and favors expression of a reporter gene under the control of the (A)gamma globin-promoter in cellular models of hemoglobin switching. *Journal of Cellular Biochemistry*, **2007**, 101, 411-24	4.7	11
64	Interleukin-3 and erythropoietin cooperate in the regulation of the expression of erythroid-specific transcription factors during erythroid differentiation. *Experimental Hematology*, **2007**, 35, 735-47	3.1	5

63	Role of thrombopoietin in mast cell differentiation. *Annals of the New York Academy of Sciences*, **2007**, 1106, 152-74	6.5	7
62	Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). *Stem Cells*, **2007**, 25, 165-73	5.8	100
61	Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia. *Molecular Pharmacology*, **2007**, 72, 1111-23	4.3	27
60	Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows. *Haematologica*, **2007**, 92, 597-604	6.6	27
59	The hypomorphic Gata1low mutation alters the proliferation/differentiation potential of the common megakaryocytic-erythroid progenitor. *Blood*, **2007**, 109, 1460-71	2.2	47
58	To code or not to code. *Blood*, **2007**, 109, 5077-5078	2.2	78
57	The return of Romeo. Scientists' international mobility and the future of research in Europe. *EMBO Reports*, **2006**, 7, 1067-71	6.5	
56	Differential amplification of murine bipotent megakaryocytic/erythroid progenitor and precursor cells during recovery from acute and chronic erythroid stress. *Stem Cells*, **2006**, 24, 337-48	5.8	23
55	The Hypomorphic Gata1low Mutation Alters the Proliferation/Differentiation Potential of the Common Megakaryocytic-Erythroid Progenitor.. *Blood*, **2006**, 108, 2549-2549	2.2	1
54	Spontaneous switch from Agamma- to beta-globin promoter activity in a stable transfected dual reporter vector. *Blood Cells, Molecules, and Diseases*, **2005**, 34, 174-80	2.1	5
53	Isolation of TPO-dependent subclones from the multipotent 32D cell line. *Blood Cells, Molecules, and Diseases*, **2005**, 35, 241-52	2.1	4
52	Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. *American Journal of Pathology*, **2005**, 167, 849-58	5.8	53
51	Ex vivo amplification of T cells from human cord blood. *Pathologie Et Biologie*, **2005**, 53, 151-8		2
50	A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. *Blood*, **2005**, 105, 3493-501	2.2	93
49	Variegation of the phenotype induced by the Gata1low mutation in mice of different genetic backgrounds. *Blood*, **2005**, 106, 4102-13	2.2	28
48	Role of GATA-1 in normal and neoplastic hemopoiesis. *Annals of the New York Academy of Sciences*, **2005**, 1044, 142-58	6.5	20
47	Pathogenesis of myelofibrosis with myeloid metaplasia: lessons from mouse models of the disease. *Seminars in Oncology*, **2005**, 32, 365-72	5.5	13
46	Expression of signal transduction proteins during the differentiation of primary human erythroblasts. *Journal of Cellular Physiology*, **2005**, 202, 831-8	7	22

45	Impaired GATA-1 expression and myelofibrosis in an animal model. *Pathologie Et Biologie*, **2004**, 52, 275-9		7
44	Not children from a lesser god. *Blood*, **2004**, 103, 368-369	2.2	
43	Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice. *Blood*, **2004**, 104, 3573-80	2.2	88
42	5-azacytidine reactivates the erythroid differentiation potential of the myeloid-restricted murine cell line 32D Ro. *Experimental Cell Research*, **2003**, 285, 258-67	4.2	5
41	GATA-1 as a regulator of mast cell differentiation revealed by the phenotype of the GATA-1low mouse mutant. *Journal of Experimental Medicine*, **2003**, 197, 281-96	16.6	189
40	Robust levels of long-term multilineage reconstitution in the absence of stem cell self-replication in W/Wv mice transplanted with purified stem cells. *Journal of Hematotherapy and Stem Cell Research*, **2003**, 12, 409-24		3
39	Placental/umbilical cord blood for unrelated-donor bone marrow reconstitution: relevance of nucleated red blood cells. *Blood*, **2002**, 100, 2662-4	2.2	41
38	Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). *Blood*, **2002**, 100, 1123-32	2.2	191
37	In vitro mass production of human erythroid cells from the blood of normal donors and of thalassemic patients. *Blood Cells, Molecules, and Diseases*, **2002**, 28, 169-80	2.1	113
36	Accentuated response to phenylhydrazine and erythropoietin in mice genetically impaired for their GATA-1 expression (GATA-1(low) mice). *Blood*, **2001**, 97, 3040-50	2.2	60
35	Identification and characterization of a bipotent (erythroid and megakaryocytic) cell precursor from the spleen of phenylhydrazine-treated mice. *Blood*, **2000**, 95, 2559-2568	2.2	75
34	Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell quantity. *Blood*, **2000**, 96, 2717-2722	2.2	250
33	Erythropoietin-dependent suppression of the expression of the beta subunits of the interleukin-3 receptor during erythroid differentiation. *Blood Cells, Molecules, and Diseases*, **2000**, 26, 467-78	2.1	1
32	Stable and unstable transgene integration sites in the human genome: extinction of the Green Fluorescent Protein transgene in K562 cells. *Gene*, **2000**, 256, 197-214	3.8	39
31	Identification and characterization of a bipotent (erythroid and megakaryocytic) cell precursor from the spleen of phenylhydrazine-treated mice. *Blood*, **2000**, 95, 2559-2568	2.2	6
30	Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell quantity. *Blood*, **2000**, 96, 2717-2722	2.2	2
29	Lineage-Restricted Expression of Protein Kinase C Isoforms in Hematopoiesis. *Blood*, **1999**, 93, 1178-1188	2.2	40
28	In vivo expansion of purified hematopoietic stem cells transplanted in nonablated W/Wv mice. *Experimental Hematology*, **1999**, 27, 1655-66	3.1	25

27	Increased expression of the distal, but not of the proximal, Gata1 transcripts during differentiation of primary erythroid cells. *Journal of Cellular Physiology*, **1999**, 180, 390-401	7	21
26	Expression Of Distal gatal Transcripts in Erythroid Cells **1999**, 249-255		
25	Thymus-Independent T Cell Differentiation in Vitro **1999**, 51-57		
24	Lineage-Restricted Expression of Protein Kinase C Isoforms in Hematopoiesis. *Blood*, **1999**, 93, 1178-1188	8.2	1
23	The making of an erythroid cell. Molecular control of hematopoiesis. *Biotherapy (Dordrecht, Netherlands)*, **1998**, 10, 251-68		9
22	Stem cell factor induces proliferation and differentiation of fetal progenitor cells in the mouse. *British Journal of Haematology*, **1998**, 101, 676-87	4.5	22
21	Outcomes among 562 recipients of placental-blood transplants from unrelated donors. *New England Journal of Medicine*, **1998**, 339, 1565-77	59.2	1175
20	Expression in hematopoietic cells of GATA-1 transcripts from the alternative "testis" promoter during development and cell differentiation. *Biochemical and Biophysical Research Communications*, **1997**, 231, 299-304	3.4	16
19	Growth factor receptor expression during in vitro differentiation of partially purified populations containing murine stem cells. *Journal of Cellular Physiology*, **1997**, 171, 343-56	7	29
18	Circulating hematopoietic stem cell populations in human fetuses: implications for fetal gene therapy and alterations with in utero red cell transfusion. *Fetal Diagnosis and Therapy*, **1996**, 11, 231-40	2.4	11
17	Circulating progenitor cells in human ontogenesis: response to growth factors and replating potential. *Stem Cells and Development*, **1996**, 5, 161-70		25
16	Functional characterization of lymphoid cells generated in serum-deprived culture stimulated with stem cell factor and interleukin 7 from normal and autoimmune mice. *Journal of Cellular Physiology*, **1995**, 164, 562-70	7	5
15	Alternatively spliced mRNAs encoding soluble isoforms of the erythropoietin receptor in murine cell lines and bone marrow. *Gene*, **1994**, 147, 263-8	3.8	13
14	Aspects of the biology of the neonatal hematopoietic stem cell. *Stem Cells*, **1993**, 11 Suppl 2, 56-64	5.8	4
13	Long-term generation of colony-forming cells (CFC) from CD34+ human umbilical cord blood cells. *Leukemia and Lymphoma*, **1993**, 11, 263-73	1.9	17
12	Induction of the murine "W phenotype" in long-term cultures of human cord blood cells by c-kit antisense oligomers. *Journal of Cellular Physiology*, **1993**, 157, 158-63	7	5
11	The generation of colony-forming cells (CFC) and the expansion of hematopoiesis in cultures of human cord blood cells is dependent on the presence of stem cell factor (SCF). *Cytotechnology*, **1993**, 11, 107-13	2.2	4
10	The biology of stem cell factor, a new hematopoietic growth factor involved in stem cell regulation. *International Journal of Clinical and Laboratory Research*, **1993**, 23, 70-7		14

List of Publications

9	Production of granulocyte colony-stimulating factor and granulocyte/macrophage-colony-stimulating factor after interleukin-1 stimulation of marrow stromal cell cultures from normal or aplastic anemia donors. *Journal of Cellular Physiology*, **1992**, 152, 199-206	7	11
8	Effects of recombinant human stem cell factor (SCF) on the growth of human progenitor cells in vitro. *Journal of Cellular Physiology*, **1991**, 148, 503-9	7	57
7	The control of proliferation and differentiation of early erythroid progenitors. *Biotherapy (Dordrecht, Netherlands)*, **1990**, 2, 299-303		3
6	Progressive inactivation of the expression of an erythroid transcriptional factor in GM- and G-CSF-dependent myeloid cell lines. *Nucleic Acids Research*, **1990**, 18, 6863-9	20.1	52
5	Human embryonic hemopoiesis: control mechanisms underlying progenitor differentiation in vitro. *Developmental Biology*, **1988**, 125, 127-34	3.1	46
4	Early hemopoietic differentiation: the action of multi-CSF is complemented by lineage specific growth factors. *Annals of the New York Academy of Sciences*, **1987**, 511, 39-49	6.5	3
3	Cloning of human erythroid progenitors (BFU-E) in the absence of fetal bovine serum. *British Journal of Haematology*, **1987**, 67, 129-33	4.5	43
2	CXCL8/CXCR2 signaling mediates bone marrow fibrosis and represents a therapeutic target in myelofibrosis		1
1	Red Blood Cells from Stem Cells257-271		